Skip to main content

Table 3 Case fatality per 1,000 patients with vivax malaria

From: Mortality attributable to Plasmodium vivaxmalaria: a clinical audit from Papua, Indonesia

  Hospitalised patients Overall population b
Age group Minimum (n/D) Upper limit a(n/D) Minimum (n/D) Upper limit (n/D)
<5 years 14.9 19.6 0.26 1.13
(95% CI 9.3 to 22.4) (95% CI 13.1 to 28.0) (95% CI 0.16 to 0.40) (95% CI 0.87 to 1.33)
(22/1,480c) (29/1,480) (22/84,028) (90.6/84,028)
≥5 years 7.0 15.1 0.07 0.45
(95% CI 3.9 to 11.8) (95% CI 10.2 to 21.5) (95% CI 0.04 to 0.11) (95% CI 0.36 to 0.55)
(14/1,986c) (30/1,986) (14/209,735) (93.8/209,735)
All 10.3 16.9 0.12 0.63
(95% CI 7.2 to 14.20 (95% CI 12.9 to 21.7) (95% CI 0.09 to 0.17) (95% CI 0.54 to 0.72)
(36/3,495) (59/3,495) (36/293,763) (184.4/293,763)
  1. aUpper limits were calculated assuming the following: 1) all of the patients for whom notes were not available died of causes related to P. vivax infection; 2) an equal number of deaths were miscoded as being attributable to P. falciparum as were miscoded as being attributable to P. vivax; bdenominators include hospital and community patients with P. vivax, estimated from the total number of cases seen in our community surveillance network multiplied by the reciprocal of the proportion who sought treatment at our network facilities (40%, established from a house-to-house survey of treatment seeking behaviour [3]). To calculate the upper limits, the same assumptions were made as in the hospitalised patients except we also multiplied the number of deaths by the reciprocal of 32% (the proportion of deaths estimated to occur outside of hospital (unpublished data)); ca small proportion of individuals in the active surveillance had an unknown age. N; number, D; denominator.